Andere Sprachen Fortress Biotech, Inc.

Aktien

A3EWWP

US34960Q3074

FBIO

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 19.04.2024			% 5 Tage	% 1. Jan.
1.75 ^USD	-3.31%		-2.78%	-41.86%

28.03.	Fortress Biotech, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
19.03.	FORTRESS BIOTECH, INC. : Alliance Global Partners bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

North American Morning Briefing : Powell Awaited -2-	03.04.
Certain Warrants of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2024.	02.04.
Certain Options of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2024.	02.04.
Certain Common Stock of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2024.	02.04.
Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights	28.03.
Avenue Therapeutics to Host Virtual Key Opinion Leader Event on April 4, 2024	26.03.
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	21.03.
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea	18.03.
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024	15.03.
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference	13.03.
Fortress Biotech to Participate in 36th Annual ROTH Conference	12.03.
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting	11.03.
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease	04.03.
Certain Preferred Stock of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2024.	08.02.
Certain Common Stock of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2024.	08.02.
Lindsay RosenwaldÃ¢€™s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries	02.02.
Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc	26.01.
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea	05.01.
Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	03.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Fortress Biotech, Inc.

Aktien

A3EWWP

US34960Q3074

FBIO

Andere Sprachen

Filter